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HIV-1 envelop gene is a major target for vaccine development. Envelop protein and its V3 loop is shown to be important deter-
minant of HIV-1 pathogenecity. Herein, the evolutionary pattern of most prevalent HIV-1 subtype B in Asia is determined by
analyzing envelop protein and V3 domain based on the 40 randomly selected sequences of HIV-1 from database (Los Alamos),
dividedintofourgroupssince1990–2007.ConstructionofenvelopproteinphylogenybyusingMEGA5exhibittheactivemutation
pattern, increase in potential N-glycosylation sites which were predicted by using online software SignalP-NN. An online available
tool Drawgram was used for multiple sequence alignment (MSA) of HIV-1 subtype B envelop region and V3 loop while the
alignment was rechecked by using CLUSTAL W and further was analyzed for GPGX motif and conserved region in V3 loop.
Variation at fourth position of the GPGX motif and 60% conservation was found in V3 loop. Hence, this diversifying pattern of
envelop protein in the Asia formulates the HIV-1 strains more pathogenic during the period of 17 years. These ﬁndings might help
inunderstandingsigniﬁcantstructuralandfunctionalconstrainsofthemutantviralstrainsandultimatelyinvaccinedevelopment.
1.Introduction
High genetic variability of HIV-1 (Human immunodeﬁcien-
cyvirusI)ischaracterizedandclassiﬁedintothreedistinctive
groups; group M (main), group O (outliner), and group N
(non-M/non-O) [1–3]. Majority of the global epidemic of
theinfectioniscausedbygroupMwhichmaybefurthersub-
divided into nine nonrecombinant subtypes (A-D, F-H, J,
and K) and at least 34 intersubtypes recombinant forms,
termed as circulating recombinant forms (CRF) [4] dis-
tributed on the basis of geographical locations. Subtype B
is circulating in United States and Europe, in addition, two
genetic forms of subtype B and CRF01-AE are dominant
in South East Asia while subtype A is most prevalent in
European countries [5].
Envelop gene plays an important role in entry and fusion
of HIV-I and is a major target for vaccine development
studies. Envelop protein gp160 is encoded by envelop gene
involved in host cell-HIV interaction. It is composed of two
noncovalently bound subunits, the external glycoprotein
gp120 and the transmembrane gp41. External glycoprotein
gp120 plays an important role in entry of the virus into the
cell by binding to the speciﬁc receptors on the surface of the
targetcell.ThesereceptorsareCD4andchemokinereceptors
known as HIV-1 coreceptors [6]. The chemokine receptors
CXCR4 and CCR5 are the two major coreceptors used by
HIV-I isolates [7]. The binding of the chemokine receptor
requires the presence of selected amino acids in gp120
(speciﬁcally within the V3 loop, and also in other regions),
providing greater aﬃnity to CCR5 or CXCR4, and therefore,
the viral tropism [8–11]. The gp120 portion of envelop has
been generally classiﬁed into ﬁve hypervariable regions (V1
to V5) with conserved regions interspersed [12]. Among
these variable regions, the V3 is one of the most important
determinants of viral tropism and coreceptor usage [13],
as it contains major antigenic and neutralizing epitopes in
HIV-1 which are well exposed upon CD4-binding [14]. This
third variable region (V3 loop) of the HIV-1 gp120 also
plays an important role in the mechanism controlling the
fusion between envelop of HIV-I and the cell membrane of
the target cells [15]. Hence, it is considered as the fusion
domain whose sole function would be to initiate the fusion
process after an initial interaction between gp120 and CD4
on the surface of the CD4+ cells [7].2 The Scientiﬁc World Journal
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Figure 1: Neighbour-joining phylogenetic tree (constructed using MEGA 5) based on amino acid sequences of envelop protein from HIV-1
subtype B in Asia.
Further, gp120 is also extensively glycosylated protein,
containing 24–26 potential glycosylation sites (24 for HIV-
INL4-3 strain, 26 for HIV-ISF2) [16]. Glycosylation of
envelop gene is crucial in all phases of HIV biology that
track from proper envelop folding, processing of virus trans-
mission, and the immune evasive mechanisms [17–19].
Therefore,thesystematicanalysisoftheglycosylationproﬁles
of envelop could provide precious insights in designing well
envelop(env)immunogens.AdecreasednumberofN-linked
glycosylationsites in gp120, especiallywithin and around the
V3 region, have been demonstrated during evolution from
R5 to the X4 phenotype [20, 21].
Several amino acids residues are extremely conserved in
V3 loop due to their functional importance among HIV-1
variants. However, the vast majority of the HIV-1 sequences,
and their putative common SIVcpz ancestors, have the
GPGX signature pattern (motif) at the central portion of
V3 loop of the envelop gene [22]. This conserved motif in
a variable region exhibits purifying selection pressure. Some
lineages, however, have been found worldwide with alternate
signature patterns, such as the GWGR subtype B variant
in which the proline residue is substituted by a tryptophan
[23, 24]. This variant was ﬁrst recorded in Japan in early
1990s[25]butaserologicstudysuggestsitspresenceinBrazil
since 1983 [17].
The present study is the ﬁrst attempt to track the
evolutionary pattern of HIV-1 in Asia over the period of 17
years. The biological activity and pathogenicity of the mostThe Scientiﬁc World Journal 3
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Figure 2: Potential N-glycosylation sites predicted from SignalP-
NN.(a)GroupI(1990–1994).(b)GroupII(1995–1999).(c)Group
IV (2005–2007). (d) Group IV (2005–2007).
prevalent HIV-1 subtype B in Asia was determined based on
the available sequences of HIV-1 in database (Los Alamos)
during the time frame of 1990–2007.
2.MaterialandMethods
Evolutionary pattern of HIV-1 subtype B was tracked by
analyzing the envelop protein and its V3 domain.
2.1. Dataset. The sequences used in the study were divided
into four groups, that is, each group constitutes the sequen-
ces from four years:
Group I: 1990–1994,
Group II: 1995–1999,
Group III: 2000–2004,
Group IV: 2005–2007.
In total, 10 sequences of HIV-1 subtype B from each
group were obtained from Los Alamos HIV database (http://
hiv-web.lanl.gov/) .T w ot y p eo fa n a l y s i sw e r ep e r f o r m e d
based on envelop protein and V3 domain of the downloaded
sequences.
2.2. Phylogenetic Analysis Based on Envelop Protein. Forty
sequences of envelop protein were randomly selected and
aligned using CLUSTALW (parameters reading DNA Pair-
wise Parameters; Gap opening penalty: 10, Gap extension
penalty: 0.1, Multiple Parameters; Gap opening penalty: 10,
Gap extension penalty: 0.2, protein weight matrix: BLO-
SUM, Residue speciﬁc penalties: ON, Hydrophilic penalties:
ON, Gap separation distance: 4, End gap separation: OFF,
negative matrix OFF, Delay divergent cutoﬀ: 30%). To
obtain phylogenetic tree alignment was analyzed in MEGA
4 tool (parameters reading; Tree inference Method: neighbor
joining, Include sites: Gaps/missing data: complete deletion,
substitution model: Amino p-distance, Substitutions to
include: All).
2.3. Prediction of N-Glycosylation Sites in Envelop Protein.
N-linked glycosylation sites of HIV-1 envelop protein were
predicted by using online software SignalP-NN.
2.4. Alignment of V3 Domain. ClustalW was used for the
alignment of V3 motifs to check the level of conservation of
this region. The conserved region was calculated manually.
2.5. Analysis of GPGX Motif. HIV-1 envelop protein sequen-
ces were aligned by using ClustalW of online software Draw-
g r a mt oﬁ n do u tc o n s e r v e dG P G Xm o t i f .
2.6. Determination of Conserved Region. Used Sequences
were aligned through multiple sequence alignment (MSA) of
ClustalW from online software Drawgram.
3. Results and Discussion
3.1. Phylogenetic Proﬁle of Envelop Protein. Phylogenetic
analysis of the envelop protein sequences in Asian strains
of subtype B was performed (Figure 1). The phylogenetic
tree representing the sequence relationships by amino acid
substitutions identiﬁed distinct genetic subgroups exhibiting
that viruses within these lineages were genetically closely re-
lated.
Isolates from 1990s make the root of the tree and also
exhibits the early evolution of the isolates. Strains from
groups year 2000 to 2004 and from 2005 to 2007 clustered
together and strains from 1990s act as their root. However,4 The Scientiﬁc World Journal
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Figure 3: Multiple sequence alignment showing the variation a GPGX motif.
strains from 1990 to 1994 make separate cluster. The clus-
tering did not correlate closely with chronological origin of
the sequences. It was observed from the clustering pattern
that strains from 1990–1995 remained resistant to selection
pressure and act as the root of the tree, while strains from
othergroups exhibit the high mutation rate demonstrated by
their branching pattern. The diﬀerences in the evolutionary
characteristics found could be attributed to a diﬀerent selec-
tion pattern of the strains by the nature.
Consequently, high mutation rate and divergence have
been shown by almost all groups while some viral lineages
have shown extensive branching pattern which may be due
to negative selection of the strains by the nature (Figure 1,
C l a d eB ,C ,D ,a n dE ) .A ni n c r e a s ei ne n v e l o p es e q u e n c e
heterogeneity has also been observed in an infected popula-
tion over the period of time [8, 9]. This increase in sequence
heterogeneity may help in viral escape from host immune
response. Other clades of the tree exhibit the strong selection
and remain less divergent over the period of time (Figure 1,
Clade A and F). The viral robustness is a key factor aﬀecting
the viral virulence which measures the capacity of a virus to
cause disease [22]. Genetic analysis of envelop gene, particu-
larly the third variable domain (V3), showed that the inter-
host(intrasubtype)variationincreasedoverthecourseofthe
AIDS epidemic [26].
3.2. Number of Predicted N-linked Glycosylation Sites. In-
crease in N-linked glycosylation sites was observed through
the period of 17 years from 1990 to 2007. This might serve to
protect viruses from neutralizing antibodies. Glycosylation
bythehostcellcanvigorouslymaneuverthefolding,stability,
and biological function of virus-encoded proteins [27, 28].
The predicted glycosylation site calculated by using the
software SignalP-NN in the period of 1990–1994 is 20, from
1995–1999 is 25, from 2000–2004 is 26, and from 2005–2007
is 30 (Figure 2).
The N-linked glycosylation (NLG) of viral envelop pro-
teins, through the formation of a ”glycan shield,” is one of
the major mechanisms for inhibiting or minimizing virus
neutralizing antibody response [29] which promotes viral
persistence and immune evasion. Further, the N-linked gly-
cosylation pattern has also been shown to have a variedThe Scientiﬁc World Journal 5
Table 1: Amino acids frequency at the fourth position of the GPGX
tetramer of V3 loop of HIV-1 subtype B.
Amino acid Percentage of subtype B isolates in Asia
Arginine (R) 73%
Glutamin (Q) 11%
Serine (S) 8%
Others 8%
eﬀect on the stimulation of neutralizing antibodies in HIV-1
[30, 31]. Consequently, alterations in glycosylation events
inﬂuencing co-receptor utilization will also allow the virus
to escape the controlling responses of the CC chemokines in
vivo, which are believed to play an eﬀective role in inhibiting
viral replication and slowing disease progression [32].
3.3. Analysis of V3 Domain. Multiple sequence alignment
(MSA) describes the variation at fourth position of the tetra-
peptide GPGX (Figure 3). Arginine remains predominant at
the fourth position while presence of serine, glutamine, and
other amino acids at this position is highly nonsigniﬁcant
(Table 1).
In HIV-1, V3 is involved in coreceptor usage [13]. This
region also contains major antigenic and neutralizing epit-
opes in HIV-1 which are well exposed upon CD4-binding
[14–17].ResiduesintheV3crown,includingtheGPGmotif,
areimportantforsolublegp120-CD4complexbindingtocell
surface receptor CCR5 [33]. The tip motif represents a target
for neutralizing antibodies [34]. Therefore, sequence varia-
tion in this motif may have an impact on virus infectivity
and disease progression.
3.4. Consensus of V3 Loop. The conserved amino acids were
calculated after aligning the V3 loop sequences. Out of 35
amino acids of the V3 loop, 21 remain the same during the
studied period. Hence, the 60% of amino acids of the V3
loop remain conserved (Figure 4). The conserved residues is
marked (∗) Figure 4.
According to previous research, some of the conserved
or relatively conserved residues are normally essential for
the biological functions of the HIV-1 [34]. The deletion or
substitution of some residues in this loop was found to aﬀect
gp120 coreceptor interactions and may further inﬂuence the
HIV-1 target entry into the host.
4. Conclusion
The present study is the ﬁrst report that demonstrated the
evolutionary pattern of HIV-1 during the period of 17 years
from 1990 to 2007. The pathogenicity and infectivity of the
HIV-1 subtype B is increased that showed the rapid evo-
lutionary and modulatory mechanism. The analyzed data
also provides useful information on the surveillance of HIV-
1 infection in Asia and highlights the evolutionary pattern
of virus populations which may be under varied selection
pressures during diﬀerent periods of time. However, further
∗ ∗ ∗∗ ∗∗∗ ∗ ∗ ∗∗ ∗ ∗∗∗∗ ∗
Figure 4: Aligned sequences exhibiting the consensus region of V3
loop (indicated by ∗).
studies are required to get more insights of all these mech-
anisms and for developing eﬀective therapies and vaccines
against HIV-1 infection.
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